Trending...
- "Global Accreditation Failures: How the Wuhan Lab Certification Exposed Systemic Weaknesses and Paved the Way for COVID-19"
- SlotCycle Raises $5.6M to Transform Secondary Gaming Equipment Market, Led by Discerning Capital
- Maryland: Preliminary Testing Confirms Highly Pathogenic Avian Influenza in Dorchester County
ELKRIDGE, Md. - Marylandian -- NEXS BioMedica Corporation, a leader in pharmaceutical innovation, is calling for urgent reforms to accelerate the development and approval of drugs targeting obesity, a chronic illness affecting over 40% of U.S. adults. The company emphasizes the need for streamlined regulatory pathways to address the growing public health and economic impact of obesity-related diseases.
"Obesity is a complex, chronic condition driving a host of life-threatening illnesses, yet it remains underrecognized and undertreated," said Dr. Marc Nelson, MD, Founder and Chairman of NEXS BioMedica. "Regulatory barriers hinder the timely delivery of innovative therapies to patients who desperately need them."
Repurposing Existing Drugs for Rapid Impact
NEXS BioMedica advocates for repurposing existing drugs with established safety profiles to expedite the creation of effective obesity treatments. Combining proven compounds with advanced delivery technologies, such as slow-release formulations, can reduce development timelines and enhance patient outcomes.
"Repurposing drugs is an underutilized strategy that could deliver solutions faster while ensuring safety and efficacy," Dr. Nelson added.
More on Marylandian
Addressing Regulatory Barriers
The company identifies several challenges that impede progress:
NEXS BioMedica urges agencies like the FDA to expand fast-track programs and prioritize research funding for obesity therapies. By reducing unnecessary delays, these reforms could save lives and reduce the $173 billion annual economic burden of obesity-related healthcare costs.
Collaborating for a Healthier Future
The company also calls for greater collaboration among pharmaceutical firms, healthcare providers, insurers, and policymakers to accelerate innovation and improve patient access to life-changing treatments.
"Addressing obesity as a chronic disease is a medical and economic imperative," said Dr. Nelson. "Streamlining drug development pathways is essential to curbing this epidemic."
About NEXS BioMedica Corporation
NEXS BioMedica is a pharmaceutical and biotechnology company pioneering therapies for weight management, chronic diseases, and metabolic disorders. Under Dr. Marc Nelson's leadership, the company leverages advanced technology to deliver transformative healthcare solutions.
Media Contact:
NEXS BioMedica Corporation
+1-571-580-2911 | media@nexsbiomedica.com | https://www.nexsbiomedica.com
"Obesity is a complex, chronic condition driving a host of life-threatening illnesses, yet it remains underrecognized and undertreated," said Dr. Marc Nelson, MD, Founder and Chairman of NEXS BioMedica. "Regulatory barriers hinder the timely delivery of innovative therapies to patients who desperately need them."
Repurposing Existing Drugs for Rapid Impact
NEXS BioMedica advocates for repurposing existing drugs with established safety profiles to expedite the creation of effective obesity treatments. Combining proven compounds with advanced delivery technologies, such as slow-release formulations, can reduce development timelines and enhance patient outcomes.
"Repurposing drugs is an underutilized strategy that could deliver solutions faster while ensuring safety and efficacy," Dr. Nelson added.
More on Marylandian
- RE1 Advisor Introduces RE1 Disaster Recovery
- Amid Controversy with The Weeknd/Playboi Carti and Buzz Surrounding His Upcoming Project, Darrin Jones Drops Soulful New Single "Under Control"
- ADHDCourses.com Launches: Transforming Parenting with Expert-Led Online Education
- Greg Welch Joins Calovia as Managing and Founding Partner
- Inframark's Mississippi Teams Expand Presence and Receive Honors from NOAA
Addressing Regulatory Barriers
The company identifies several challenges that impede progress:
- Lengthy and expensive clinical trial requirements for chronic conditions.
- Limited expedited pathways for combination therapies or repurposed drugs.
- Insufficient recognition of obesity as a chronic illness requiring long-term treatment.
NEXS BioMedica urges agencies like the FDA to expand fast-track programs and prioritize research funding for obesity therapies. By reducing unnecessary delays, these reforms could save lives and reduce the $173 billion annual economic burden of obesity-related healthcare costs.
Collaborating for a Healthier Future
The company also calls for greater collaboration among pharmaceutical firms, healthcare providers, insurers, and policymakers to accelerate innovation and improve patient access to life-changing treatments.
"Addressing obesity as a chronic disease is a medical and economic imperative," said Dr. Nelson. "Streamlining drug development pathways is essential to curbing this epidemic."
About NEXS BioMedica Corporation
NEXS BioMedica is a pharmaceutical and biotechnology company pioneering therapies for weight management, chronic diseases, and metabolic disorders. Under Dr. Marc Nelson's leadership, the company leverages advanced technology to deliver transformative healthcare solutions.
Media Contact:
NEXS BioMedica Corporation
+1-571-580-2911 | media@nexsbiomedica.com | https://www.nexsbiomedica.com
Source: NEXS BioMedica Corporation
0 Comments
Latest on Marylandian
- Alliance Homecare Appoints Amy Romero as CMO to Drive Growth of TrustHouse, Private In-Home Nursing and Concierge Care
- Windsor Brokers Launches 2% Interest on all Trading Accounts
- JAS Canvases Now Available Online
- DMV Jazz Series Brings the Warren Wolf-Allyn Johnson Experience to New Spire Arts
- K9 Technology President Files a Lawsuit Against Google LLC
- InventHelp Inventor Develops Modified State-Issued License Plate (DCD-433)
- RE1 Advisor Announces the Hiring of Brenda Schuyler
- Uriel Medrano Joins RE1 Advisor as Property Manager/Realtor
- Maryland: MARBIDCO Certified Local Farm and Fish Food Aggregation Grant Fund Now Open
- OneSolution® Dental Implant Centers Celebrates Over 15,000 Successful Full-Arch Cases
- Des Moines Home Buyers, LLC: Trusted Professionals Offering Cash for Houses Since 2006
- K2 Integrity Appoints Jason Straight as Senior Managing Director for Cyber Resilience and Digital Risk Advisory Practice
- New Organizational Assessment Helps Nonprofits Build Stronger Foundations
- 7 years ago a vision was born. Today 700+ clients are thriving with Cyntexa's expertise
- Infinity Garage Door Repair Offers 24/7 Emergency Service & Smart Home Upgrades in Las Vegas
- SlotCycle Raises $5.6M to Transform Secondary Gaming Equipment Market, Led by Discerning Capital
- Integris Composites Debuts its Concealed Response Shield System; 'Situational Armor' for Active-Shooter Responders When Seconds Count
- FOLKS Expands With The Launch Of FOLKS USA
- Safe Night Partners With Simsi To Offer A New Certification For Proactive Alliance With Rutgers University
- InventHelp Inventor Develops New Shoe Sanitizing Mat (BDH-346)